Sellas Life Sciences has completed the 80th event in its Phase 3 REGAL trial of Galinpepimut-S for acute myeloid leukemia. The trial is designed to measure the drug's efficacy, with preliminary results expected this quarter. Analysts note that prolonged trial durations may raise the likelihood of failure. The company continues to monitor the trial's progress closely, with updates expected as the trial progresses. The REGAL trial is a major step in the development of Galinpepimut-S, which has shown promising results in previous phases. Sellas Life Sciences remains committed on advancing the drug through the regulatory process, with the goal of bringing a potential treatment to patients with acute myeloid leukemia. The company's careful approach to clinical trials and data analysis is strongly regarded in the industry, and investors are monitoring the trial's outcome with interest.